Company intelligence / Profile preview

GuoDa

Ownership: Private
Employees: ~30000
Development stage: Commercial

Overview

The main biotech product associated with the "Guoda" name via its affiliate/subsidiary GDBio Pharmaceutical Co. Ltd./Qingdao Guoda Biopharmaceutical is recombinant streptokinase, an enzyme therapy targeting plasminogen for thrombolysis in myocardial infarction patients. This product received regulatory approval in China on October 16, 2002. No recent clinical trial data or new pipeline programs are publicly disclosed.

Therapeutic areas: Cardiovascular
Modalities: Enzyme
Industry: Biotech

Beyond the preview

Go deeper on GuoDa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GuoDa.

Explore the full profile